Repligen Corp

NASDAQ: RGEN
$131.39
-$1.29 (-1.0%)
Closing Price on July 24, 2024

RGEN Chart and Intraday Price

RGEN Company Data

Asset Type Stock
Exchange NASDAQ
Currency USD
Country USA
Sector LIFE SCIENCES
Industry BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Address 41 SEYON STREET, BUILDING 1, SUITE 100, WALTHAM, MA, US
Fiscal Year End December
Latest Quarter 12/31/2023
Market Cap 10,904.37M USD
Shares Outstanding 55,771,000
Repligen Corporation is a pioneer in bioprocessing technologies, playing a crucial role in the manufacturing of biological drugs globally. With a product lineup that includes Protein A ligands essential for drug purification, innovative chromatography columns like OPUS, and a range of filtration devices, Repligen supports the biopharmaceutical industry's need for high-quality drug production. Their offerings extend to ELISA test kits and process analytics products, catering to life sciences, diagnostics, and biopharmaceutical companies. Founded in 1981 and based in Waltham, Massachusetts, Repligen is committed to advancing biomanufacturing with its collaborative and innovative solutions.

RGEN Articles

Wednesday's top analyst upgrades and downgrades included Array Technology, Blink Charging, Carnival, Carrier Global, DocuSign, Fox, Marathon Petroleum, Occidental Petroleum, PagSeguro Digital,...
Thursday's top analyst upgrades and downgrades included Amgen, Archer Daniels Midland, Blackstone, Bloom Energy, Carnival, Chevron, Danaher, EQT, KKR, Nike, PACCAR, Plug Power, PulteGroup,...
Tuesday's top analyst upgrades and downgrades included Ally Financial, CarMax, Dominion Energy, Dynatrace, Exelon, GigaCloud Technology, Gilead Sciences, Intuit, KKR, Lowe’s Companies, Morgan...
For health care investors, 2020 looks like a potentially good year after an especially fruitful JPMorgan Healthcare Conference this past week.